Major Depressive Disorder Clinical Trial
Official title:
Double-Blind, Placebo Controlled Trial of Metyrapone as Augmenting Agent in the Treatment of Major Depression
The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.
The investigators' understanding of the neuroendocrine pathophysiology of depression has
made significant progress in recent years, which should help to develop new remedies.
Alterations of the hypothalamic-pituitary-adrenocortical (HPA) axis are the most consistent
pathological endocrine findings in depression. Hence, attempts have been made to treat
depression by directly targeting HPA-axis activity. Currently, three major pathways are
investigated:
- Administration of CRH-antagonists;
- Administration of glucocorticoid-receptor-antagonists; and
- Treatment with steroid-synthesis inhibitors like ketoconazole, aminogluthethimide or
metyrapone.
The investigators' aim was to conduct the first prospective, randomized, placebo-controlled,
double-blind clinical trial of metyrapone as additive treatment in depression. Metyrapone
was preferred, since this compound inhibits selectively the 11β-hydroxylase and the
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1), thereby exerting direct effects within
the central nervous system (CNS). The additive approach was applied because the intended
inclusion of severely depressed patients made a pure placebo group ethically challenging.
Furthermore, the continuous use of an antidepressant allowed a standardized follow up after
the double-blind period.
The hypotheses to be tested were, whether metyrapone exerts potentiating effects during a
standard antidepressant therapy and whether an earlier onset-of-action and an improved
overall and sustained treatment response can be achieved. Since GR/MR distribution as well
as 11β-HSD-1 activities are subject to sexual dimorphism in humans, the sample was
prospectively stratified for gender and balanced for treatment with two selected
serotonergic antidepressants, allowing further analysis of gender effects and neuroendocrine
treatment effects.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |